Hesketh PJ - Search Results

1

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ. Hesketh PJ, et al. Eur J Cancer. 2003 May;39(8):1074-80. doi: 10.1016/s0959-8049(02)00674-3. Eur J Cancer. 2003. PMID: 12736106

2

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group. Hesketh PJ, et al. J Clin Oncol. 2003 Nov 15;21(22):4112-9. doi: 10.1200/JCO.2003.01.095. Epub 2003 Oct 14. J Clin Oncol. 2003. PMID: 14559886 Clinical Trial.

3

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ. Warr DG, et al. Among authors: hesketh pj. Eur J Cancer. 2005 Jun;41(9):1278-85. doi: 10.1016/j.ejca.2005.01.024. Eur J Cancer. 2005. PMID: 15939263

4

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.

Hesketh PJ, Aapro M, Street JC, Carides AD. Hesketh PJ, et al. Support Care Cancer. 2010 Sep;18(9):1171-7. doi: 10.1007/s00520-009-0737-9. Epub 2009 Sep 12. Support Care Cancer. 2010. PMID: 19756774 Clinical Trial.

5

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ. Hesketh PJ, et al. Support Care Cancer. 2006 Apr;14(4):354-60. doi: 10.1007/s00520-005-0914-4. Epub 2006 Feb 1. Support Care Cancer. 2006. PMID: 16450086 Clinical Trial.

6

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ. Chawla SP, et al. Among authors: hesketh pj. Cancer. 2003 May 1;97(9):2290-300. doi: 10.1002/cncr.11320. Cancer. 2003. PMID: 12712486 Free article. Clinical Trial.

7

Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).

Hesketh PJ, Warr DG, Street JC, Carides AD. Hesketh PJ, et al. Support Care Cancer. 2011 Sep;19(9):1297-302. doi: 10.1007/s00520-010-0944-4. Epub 2010 Jul 11. Support Care Cancer. 2011. PMID: 20623144 Clinical Trial.

8

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ. Navari RM, et al. Among authors: hesketh pj. N Engl J Med. 1999 Jan 21;340(3):190-5. doi: 10.1056/NEJM199901213400304. N Engl J Med. 1999. PMID: 9917226 Free article. Clinical Trial.

9

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F; Aprepitant Moderately Emetogenic Chemotherapy Study Group. Herrstedt J, et al. Among authors: hesketh pj. Cancer. 2005 Oct 1;104(7):1548-55. doi: 10.1002/cncr.21343. Cancer. 2005. PMID: 16104039 Free article. Clinical Trial.

10

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM. Hesketh PJ, et al. J Clin Oncol. 1997 Jan;15(1):103-9. doi: 10.1200/JCO.1997.15.1.103. J Clin Oncol. 1997. PMID: 8996130 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

193 results

Search Page

Filters